Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063491 | PMC |
Am J Case Rep
January 2025
Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Mie, Japan.
BACKGROUND Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system's ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.
View Article and Find Full Text PDFCureus
June 2024
Pulmonary and Critical Care Medicine, Jersey Shore University Medical Center, Neptune, USA.
Respirol Case Rep
June 2024
Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran.
The visualization of black pigment during EBUS-TBNA suggests a relapse of melanoma. This case highlights the value of EBUS-TBNA in diagnosing metastatic melanoma, particularly when the macroscopic appearance of the aspirate suggests the diagnosis.
View Article and Find Full Text PDFArch Bronconeumol
May 2024
University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. Electronic address:
BMC Pulm Med
February 2024
Interventional Pulmonology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!